HOUSTON--(BUSINESS WIRE)--Oncolin Therapeutics, Inc. (OTCBB:OCOL) is pleased to announce that Dr. Waldemar Priebe has agreed to join the Scientific Advisory Board (SAB) as a member and to assume the role of a Chairman of the SAB. Dr. Priebe is a Professor of Medicinal Chemistry at the University of Texas M. D. Anderson Cancer Center where he is a member of the Department of Experimental Therapeutics. Dr. Priebe is the author of over 150 papers and inventor of numerous patents. He has had a very successful record in cancer drug discovery and early stage development of a number of cancer therapeutics with 3 drugs currently in clinical trials and several in pre-clinical development. Dr. Priebe’s oncology interests span a wide number of mechanistic areas including being the founding scientist of Oncolin’s glycolysis inhibitors.
